Biotherapeutics and Antibody Analysis
Because of their high specificity and targeted effects, monoclonal antibodies (mAbs), Fc fusions and antibody-drug conjugates (ADCs) are the new generation of cancer and autoimmune disease therapies. Modern principles of Quality by Design (QbD) mandate controlled production and dedicated quality controls to ensure their effectiveness and safety.
- The majority of biotherapeutics are glycosylated proteins produced recombinantly in mammalian cells.
- N-glycans are essential for effector functions in mAbs, but they can also carry xenoantigens (i.e. α-Gal epitope).
- The impact of glycosylation on protein function, structure and safety makes it a critical quality attribute (CQA), measured throughout development and production.
- Additionally, batch-to-batch glycosylation consistency is used as a surrogate measure of process control.
- Analysis of sequence variants is facilitated by glycan removal.
- Antibody fragmentation with specific proteases allows the analysis of intact, glycosylated, Fc and Fab fragments.
Featured Articles:
- Proteomics: Fast and Efficient Antibody Deglycosylation using Rapid PNGase F
- Characterization of glycans from Erbitux®, Rituxan® and Enbrel® using PNGase F (Glycerol Free), Recombinant
- Glycan analysis of murine IgG by enzymatic digestion with Endo S and PNGase F, followed by mass spectrometric analysis
- Unbiased and fast IgG deglycosylation for accurateN-glycan analysis using Rapid PNGase F
References:
- Zhang L, et al (2016) MAbs. 2016; 8(2):205-15. PMID 26599345.
- Hakemeyer C, et al (2016) Biologicals 2016; 44(5):306-18. PMID 27464992.
Choose Type:
- Vainauskas, S., Kirk, C.H., Petralia, L., Guthrie, E.P., McLeod, E., Bielik, A., Luebbers, A., Foster, J.M., Hokke, C.H., Rudd, P.M., Shi, X., Taron, C.H (2018) A novel broad specificity fucosidase capable of core a1-6 fucose release from N-glycans labeled with urea-linked fluorescent dyes Sci Rep; PubMedID: 29934601, DOI: 1038/s41598-018-27797-0
- Albrecht, S., Vainauskas, S., Stöckmann, H., McManus, C., Taron, C.H. and Rudd, P.M. (2016) Comprehensive Profiling of Glycosphingolipid Glycans Using a Novel Broad Specificity Endoglycoceramidase in a High-Throughput Workflow. Anal Chem; May 3;88(9), 4795-802. Anal Chem.. PubMedID: 27033327
Products and content are covered by one or more patents, trademarks and/or copyrights owned or controlled by New England Biolabs, Inc (NEB). The use of trademark symbols does not necessarily indicate that the name is trademarked in the country where it is being read; it indicates where the content was originally developed. All other trademarks are the property of their respective owners. The use of this product may require the buyer to obtain additional third-party intellectual property rights for certain applications. For more information, please email busdev@neb.com.
This product is intended for research purposes only. This product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
